Alx Oncology Holdings (ALXO) EBIT Margin (2019 - 2020)
Alx Oncology Holdings (ALXO) posted EBIT Margin of 2046.87% for Q2 2020, down 155.76% sequentially from 800.31% in Q1 2020, and down 172339.0% YoY from N/an in Q3 2019.
Powered by 
Analysis
Alx Oncology Holdings (ALXO) EBIT Margin (2019 - 2020) Analysis & Trends
Alx Oncology Holdings has reported EBIT Margin for 2 years, with the latest figure at 2046.87% in Q2 2020.
- Quarterly EBIT Margin fell 172339.0% year-over-year to 2046.87% in Q2 2020, while the trailing twelve-month figure through Mar 2021 was 9986.53% (down 952946.0% YoY) and the FY2020 annual result came in at 3693.99%, down 329401.0% from the prior year.
- EBIT Margin declined to 2046.87% in Q2 2020 per ALXO's latest filing, from 800.31% in the prior quarter.
- Over five years, EBIT Margin peaked at 241.56% in Q3 2019 and troughed at 2046.87% in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - | 19.75% |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -0.36% |
| 10 | Alx Oncology Holdings | 273.99 Mn | 273.99 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2020 | -2,046.87% |
| Mar 31, 2020 | -800.31% |
| Dec 31, 2019 | -637.51% |
| Sep 30, 2019 | -241.56% |
| Jun 30, 2019 | -323.47% |